Glass House Eyes European Cannabis Exports After GACP Certification

Glass House Brands (NYSE: GLAS) has secured Good Agricultural and Collection Practice (GACP) certifications for two California cultivation facilities, advancing its strategy to enter international medical cannabis markets where compliant production can command higher prices.

The company’s Casitas and Padaro farms received certification on October 11, covering more than 500,000 square feet of greenhouse cultivation.

The certifications establish compliance with agricultural quality and safety standards relevant to European medical cannabis supply chains. Germany, the United Kingdom and Switzerland are among the markets Glass House is targeting.

“Once we can export, medical markets like Germany, the UK and Switzerland […] will dramatically expand our total addressable market,” said CEO Kyle Kazan, who also pointed to opportunities for higher pricing, profitability and cash generation.

What About Federal Restrictions?

GACP certification does not authorize cannabis exports. Glass House still needs the appropriate U.S. federal permissions and import-country approvals.

The company has already pursued registration with the Drug Enforcement Administration for federally regulated medical cannabis operations. Such registrations could provide a legal framework for manufacturing, distribution, and export if the applicable federal rules permit those activities. Export shipments would also require separate regulatory authorizations.

Glass House has previously exported federally compliant CBD hemp biomass to Europe, but exporting marijuana for medical use involves a different, more restrictive regulatory process.

Why This Matters for Cannabis M&A

The announcement reinforces a point raised by cannabis dealmaker Seth Yakatan in a recent IgniteIt interview on Curaleaf, Aurora and Vireo.

Yakatan argued that large-scale cultivation assets capable of meeting European medical standards could become increasingly valuable as international operators compete for reliable supply.

“I think what you also see is a repricing of the EU-GMP assets as a result of it,” Yakatan said, specifically identifying Glass House as a potential beneficiary of that trend.

Glass House’s GACP certification is not equivalent to EU-GMP manufacturing approval, but it moves the company toward participation in those supply chains. Whether that translates into higher margins will depend on federal export authorization, additional compliance requirements, and commercial agreements.

The changing economics of international cannabis production, asset valuations, and cross-border investment will be among the topics at IgniteIt’s Capital & Policy Summit in Washington, D.C., on November 18, bringing together executives, investors, and policymakers to discuss the industry’s next phase.